. 2020 Aug 3;10:13031. doi: 10.1038/s41598-020-69007-w

Table 1.

Table of vaccination strategies for trials studied.

Trial arm	Strategy	Products	Envelope	Month
Trial arm	Strategy	Products	Envelope	0	1	2	3	4	6	8	10
097-T1	CCPP	vCP1521, AIDSVAX	gp120	C	C		C + P		C + P
097-T2	CCPP	vCP1521, AIDSVAX	gp120	C	C		C + P		C + P
105-T2	DDPP	HIV-PT123, AIDSVAX	gp140, gp120	D	D		P		P
105-T3	DDD/P	HIV-PT123, AIDSVAX	gp140, gp120	D	D		D + P		D + P
105-T4	D+P	HIV-PT123, AIDSVAX	gp140, gp120	D + P	D + P		D + P		D + P
094-T1	DDMM	GEO-D03, MVA/HIV62B	gp160, gp150	D		D		M	M	M
094-T2	DDMMM	GEO-D03, MVA/HIV62B	gp160, gp150	D		D		M	M		M
094-T3	DDMM	GEO-D03, MVA/HIV62B	gp160, gp150	D		D		M		M
205-T1+3	DDMM	JS7, MVA/HIV62	gp160, gp150		D		D		M	M
205-T4	MMM	MVA/HIV62	gp160, gp150	M		M			M

Main trials considered in this study (additional trials are in Supplementary information). Envelope gives which component of the envelope was included in the trial vaccines. Blank indicates no injection given at month. All protein vaccines here use AIDSVAX B/E. C indicates Canarypox vector, P indicates protein, D indicates DNA, rAd represents recombinant adenovirus and M represents Modified vaccinia ankara.